1. Why This Review Matters
A continuation lets you pursue new claims from an earlier disclosure while keeping the earlier filing date. It works only if the continuation adds nothing to that disclosure. Two separate exposures follow from a failure:
- During examination. New matter in the specification is objected to and must be cancelled, and claims that rely on it are rejected for lack of written description.
- After grant. Even if the claims issue, a claim the parent doesn’t support isn’t entitled to the parent’s date. Anything published or sold between the two filing dates then becomes prior art, and that can include the applicant’s own parent publication.
Recent Federal Circuit decisions show how this plays out in litigation:
- In Enanta Pharmaceuticals v. Pfizer (June 23, 2026), the court held the patent was not entitled to its provisional’s filing date because the provisional did not adequately describe the later-claimed subject matter. The provisional defined a substituent as C2-C12 alkyl, while the claims covered C1-C12. Pfizer’s intervening public disclosure then became anticipatory prior art, and summary judgment of invalidity was affirmed. The chain included several continuations, and none of them repaired the missing support. Saul Ewing LLPSaul Ewing LLP
- In Seagen v. Daiichi Sankyo (Dec. 2, 2025), the court held that a priority application that broadly outlined a huge range of linker peptides did not support later claims to a specific glycine/phenylalanine tetrapeptide subgenus, and the patent fell to the accused product’s public disclosure. Akin Gump
The lesson from both cases is that support has to exist in the earlier text, and a later filing cannot supply it. The claim review described below is how a drafter confirms that support before filing, and again each time the claims change.
2. The Legal Framework in Brief
What a continuation is
A continuation is an application for the invention disclosed in a prior-filed copending application, and its disclosure must not include any subject matter that would be new matter if submitted as an amendment to the parent. Its inventorship must include at least one inventor named in the prior-filed application, and it must claim the earlier application’s benefit. BitLawBitLaw
If you need to add material, the vehicle is a continuation-in-part. A CIP is filed during the life of the earlier application, repeats some substantial portion or all of it, and adds matter not disclosed in it. BitLaw
The new matter rules
- 35 U.S.C. 132 and 251 prohibit new matter in amendments to applications and reissues respectively. Centralcoastpatent
- New matter added to the claims leads to a written description rejection under 112(a), and new matter added to the specification, abstract, or drawings is objected to and must be cancelled. CentralcoastpatentCentralcoastpatent
- Claims as originally filed are part of the disclosure, so an original claim can support later specification text (In re Benno). BitLaw
- New matter is broader than obviously unsupported additions. It can include adding specific percentages or compounds after a broader original disclosure, or even omitting a step from a method. Uspto
- Preliminary amendments are a trap. A preliminary amendment present on the filing date is treated as part of the original disclosure for applications filed on or after September 21, 2004. That makes it part of the continuation’s disclosure, but it is still new matter relative to the parent if the parent lacks it. In that case the application is no longer a true continuation. Aipla
Formal benefit requirements
- The benefit claim must be made during pendency, and for an application filed under 111(a) within the later of four months from the actual filing date of the later-filed application or sixteen months from the filing date of the prior-filed application. BitLaw
- For applications filed after September 16, 2012, the specific reference to the prior application must be included in an application data sheet. BitLaw
- If a chain reaches back before March 16, 2013 and the continuation has a claim with an effective filing date on or after that date, a statement to that effect is required within the deadline set out in 37 CFR 1.78. This AIA-transition statement is easy to miss, and it also forces a claim-by-claim look at which claims are entitled to which date. LawServer
Two questions that look alike
Reviewers often blur two questions. The first is whether the continuation’s specification adds anything. The second is whether each claim is supported by the parent. A continuation can copy the parent word for word and still contain a claim the parent doesn’t support, because a claim can be drafted to cover something the text never described. A complete review answers both.
3. Where New Matter Enters a Continuation
A. Specification “clean-up”
The usual origin of new matter is a well-meant edit. Common examples:
- Updating terminology to modern usage or the client’s product vocabulary.
- Adding definitions “for clarity.”
- Fixing an apparent error, such as a substituent range, a temperature, or a sequence.
- Adding examples, data, or embodiments from later work.
- Rewriting the background or summary to align with new claims.
Error correction deserves special care. A correction is safe only when a skilled reader would recognize both the error and the correct fix from the disclosure itself. Enanta shows how narrow that is. The applicant said the “C2” was a typo for “C1.” The court asked a different question, namely whether the earlier document showed possession of the C1 compounds. It did not, and other passages suggesting the error was likely a mistake did not supply support for the specific substituent. Saul Ewing LLP
B. Claim drafting techniques that go beyond the parent
| Technique | Why it’s risky | What to check |
| Narrowing to a subgenus or sub-range | A broad genus or range does not automatically describe every subset (Seagen, Wertheim) | Is the subset expressly disclosed, or at least clearly pointed to (a preferred embodiment, an example, or a named endpoint)? |
| Broadening by dropping a limitation | The omitted feature may have been presented as essential | Does the parent describe the invention without it, or say it is required? |
| Combining features from separate embodiments | “Picking and choosing” may create a combination never disclosed | Is there a disclosed embodiment or a clear pointer that puts these features together? |
| Negative limitations | Excluding something needs a basis in the text | Does the parent state the exclusion, or describe reasons to exclude the element? |
| New numerical endpoints | Endpoints not stated in the parent are a classic new matter issue | Are both endpoints, or a disclosed range that contains them, in the text? |
| Functional or result-based language | The parent may describe structures only | Does the text describe the function and the range of structures that achieve it? |
| New claim terms | A synonym may broaden or shift meaning | Is the term used in the parent, or defined equivalently? |
| Omitting a method step | Treated as new matter in the MPEP | Does the parent describe the process without that step? |
| Changing claim category (product, method, use, system) | Support for one category is not automatically support for another | Is each category described, with the features the new claim recites? |
| Percent identity or variant claims | Specific thresholds or variants may not be disclosed | Are the thresholds, and the variants they include, expressly disclosed? |
C. Drawings, chemical structures, and sequences
Figures and structural formulae are part of the disclosure, so changing or replacing them can add matter. Sequence listings need particular care:
- For applications with a filing date on or after July 1, 2022, an XML listing under ST.26 is required. The USPTO says a continuation filed after that date must include an ST.26 listing even if the parent has an ST.25 listing, so the papers cannot be an exact copy of the parent’s. USPTO
- Conversion is not per se new matter. The USPTO says compliance with the ST.26 rules is not per se a new matter issue. But conversion choices, such as how modified residues are annotated or which short sequences are omitted, must not add information the parent lacks. Compare the converted listing against the parent’s listing line by line. uspto
The companion article in this series on sequence listing considerations for new-modality biologics covers ST.26 representation choices in more detail.
D. Incorporation by reference and data
Material can generally not be brought in by adding an incorporation-by-reference statement after filing, so check whether the parent’s incorporation language was present as filed and whether the incorporated document is being relied on. Likewise, new experimental results can be presented to the Office as evidence (for example, in a declaration on unexpected results) but cannot be added to the specification. Evidence of this kind does not cure a lack of written description.
4. A Step-by-Step Claim Review Workflow
Step 1: Fix the record
Gather, for every application in the chain, the specification, drawings, claims, and sequence listing as originally filed. Also collect all amendments, the application data sheets, and any provisional. Review against the as-filed text, not the issued patent, since the issued patent may reflect amendments. Note the chain’s dates, in particular whether it straddles March 16, 2013.
Step 2: Redline the continuation specification against the parent
Compare the two texts and classify every difference as formal (cross-references, headings), clarifying, or substantive. The safest continuation is the parent’s text with only the updated cross-reference. Any substantive difference needs an explicit support citation or should be removed. If several substantive differences are needed, that is a signal to consider a CIP.
Step 3: Build a claim support chart
For each claim and each limitation, record where the parent supports it. A workable format:
| Claim limitation | Parent citation (paragraph or figure) | Support type | Risk |
| “wherein R is ethyl” | ¶ 24, Example 3 | Express (named species) | Low |
| “a dose of 15-30 mg/kg” | ¶ 31 states 10-50 mg/kg, preferred 20 mg/kg | Sub-range of a broader range | High |
| “free of excipient X” | Not mentioned | None (negative limitation) | High |
The test is whether the parent, read as a whole, reasonably conveys to a skilled person that the inventor had possession of the claimed invention at the earlier filing date (the Ariad standard). Exact wording is not required, but a bare genus plus an invitation to experiment is not enough, as Seagen illustrates. A patentee’s expert describing the claim as a straightforward leap from the disclosure was described by the court as self-defeating, because what one must leap to is not there. Treat any support argument that relies on “obvious from the disclosure” as a warning sign. Akin Gump
Step 4: Run the specialized audits
- Terminology audit. Trace every claim term to the parent, and flag new terms.
- Range and number audit. Check every endpoint, unit, and “about.”
- Genus/species audit. For each narrower claim, find the express pointer to the narrower group.
- Negative and omission audit. For every exclusion or dropped element, find the disclosure that supports it.
- Combination audit. For claims joining features from different passages, find the passage that joins them.
- Figure, formula, and sequence audit. Compare structures, ranges, and sequences character by character, since Enanta turned on a single-carbon difference.
- Claim category audit. Confirm each category (compound, composition, method, use) is described.
Step 5: Decide on entitlement and route
| Result of the review | Options |
| All claims supported | File the continuation with the benefit claim; keep the support chart in the file |
| Some claims unsupported | Rewrite those claims to what is disclosed; or split them into a CIP; or accept that they receive only the later date and assess the intervening art |
| New matter needed for the commercial embodiment | File a CIP, understanding that supported claims can keep the parent date while new-matter claims get the CIP date |
| Parent publication is a risk to new-matter claims | Consider whether the new-matter claims are patentable over your own parent publication before filing at all |
A CIP is not a free option. Its new-matter claims carry the later date, and the parent’s publication can be prior art against them. Also note that a patent’s term generally runs from the earliest non-provisional application in the benefit chain, so a long chain of continuations shortens the effective term from the date the first was filed.
Step 6: Build the prosecution record
When you present new or amended claims, the MPEP says applicants should specifically point out the support for amendments made to the disclosure. Doing so early speeds examination, but be precise. A support citation that overstates what the parent says can become an admission or narrow the claim later. BitLaw
Step 7: Repeat whenever claims change
Every amendment, new claim set, or request for continued examination re-opens the question. Keep the support chart alive and update it for each claim change. Across a large family, maintain a single matrix showing which claims are entitled to which date.
5. A Worked Illustration (Hypothetical)
Suppose the parent discloses a compound of formula I in which R is C2-C12 alkyl. Its example section names R = ethyl and R = propyl, and it describes a treatment method with a dose of 10-50 mg/kg, preferably 20 mg/kg, “optionally with an excipient.”
| Proposed continuation claim | Assessment | Reasoning | Fix |
| 1. Compound of formula I where R is C1-C12 alkyl | Not supported | C1 was never disclosed, and a near neighbor is not the same disclosure (the Enanta analogy) | Claim C2-C12, or file a CIP with C1 support |
| 2. Compound where R is ethyl | Supported | Named species and example | None |
| 3. Method with a dose of 15-30 mg/kg | High risk | A sub-range of a broader range with no stated endpoints | Claim 10-50 mg/kg, or a supported point such as 20 mg/kg |
| 4. Composition “free of excipient X” | High risk | Negative limitation with no disclosed basis | Claim positively what is disclosed |
| 5. Method omitting the second administration step | High risk | Omitting a step can be new matter, especially if the parent presents it as part of the method | Keep the step, or show the parent describes the method without it |
| 6. Method comprising administering the compound | Depends | Supported only if “administering” is generic in the parent and no route is presented as essential | Confirm the parent’s wording |
The point is that most of these are not obviously wrong on a quick read. They fail only when a limitation-by-limitation chart is compared against the parent’s text.
6. Field-Specific Traps
| Field | Frequent problem |
| Chemistry and pharma | Definitions of substituents and variables, generic formulae versus species, ranges, salts and polymorphs, and (as in Enanta) single-atom differences |
| Biotech | Percent identity thresholds, fragments and variants not expressly disclosed, functional antibody claims, sequence listing conversions |
| Software and AI | Functional claim language without described algorithms, new “module” or “model” terminology, system-versus-method category shifts |
| Mechanical and devices | Features shown only in drawings, dimensions and angles, omitted elements described as essential, reference numerals removed |
| Diagnostics | Thresholds, cut-offs, and sample types not stated in the parent |
7. A Note on Prior Art Runs in the Other Direction
Support analysis also helps when someone else’s continuation or provisional is cited against you. In Dental Monitoring v. Align (Aug. 10, 2026), the Federal Circuit held that a published application receives its provisional’s filing date for prior-art purposes only if the provisional provides written description support under 112(a) for at least one claim of the published application. The same skills used to review your own continuation’s support apply to testing whether a reference deserves the earlier date it claims. Iplawwatch
8. Pre-Filing Checklist
- Collect the as-filed documents for every application in the chain, plus all amendments.
- Confirm copendency, a common inventor, and the benefit claim in the application data sheet within the time limits.
- Check whether the chain crosses March 16, 2013 and, if so, whether a transition statement is needed.
- Prepare a redline of the continuation specification against the parent and eliminate or justify every substantive change.
- Confirm any preliminary amendment adds nothing beyond the parent.
- Build a claim-by-claim, limitation-by-limitation support chart with paragraph citations.
- Run the terminology, range, genus/species, negative-limitation, omission, and combination audits.
- Compare figures, formulae, and sequences with the parent, including any ST.25-to-ST.26 conversion.
- Decide the route (continuation, CIP, or new application) for any unsupported claim, with the intervening-art risk assessed.
- Record support citations in the file, keeping statements accurate and no broader than the parent.
- Repeat the review for every later claim amendment.
Conclusion
A continuation is only as good as the parent it repeats. The review that protects it is a mechanical, claim-by-claim comparison against the as-filed text, done before filing and repeated whenever the claims change. Recent cases show the cost of skipping it: patents lost to intervening disclosures because a single carbon or a narrow subgenus was never described. Treat support as something to be demonstrated with citations, choose a CIP when you truly need new matter, and accept that claims the parent doesn’t support get only the later date.